Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCTID	NCT05836259 (View at clinicaltrials.gov)
Description	This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene. (Show More)
Development Status	Active
Indication	Hypertrophic Cardiomyopathy
Disease Ontology Term	DOID:0110310
Compound Name	TN-201
Sponsor	Tenaya Therapeutics
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	30
Results Posted	Not Available

Target Gene/Variant	MYBPC3
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Functional gene replacement
Route of Administration	Intravenous
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV9
Editor Type	none
Dose 1	3E13 vg/kg
Dose 2	6E13 vg/kg
Dose 3
Dose 4
Dose 5

No.of Trial Sites	10
Locations	United States

Has US IND	True
FDA Designations
Recent Updates	Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25